Hims Expands Men’s Health Services With New Injectable and Oral Testosterone Replacement Therapy Options
Hims & Hers Health, Inc., a digital healthcare platform focused on personalized health and wellness services, has announced a significant expansion of its men’s health program with the introduction of injectable and oral testosterone replacement therapy (TRT) options. The new offerings are designed to provide eligible men experiencing low testosterone with additional treatment choices through a care model that combines at-home blood collection, laboratory testing and consultations with licensed healthcare providers.
Testosterone is a hormone that plays an important role in several aspects of men’s health, including sexual function, muscle maintenance, bone health, red blood cell production and overall well-being. Although the hormone is often associated with physical strength and muscle development, its functions extend far beyond athletic performance. In men with clinically low testosterone levels, a deficiency can contribute to symptoms such as persistent fatigue, reduced libido, erectile dysfunction, changes in body composition and depressed mood.
Despite the potential effects of low testosterone on daily life, many men may not recognize the symptoms or seek medical evaluation. Social stigma, uncertainty about treatment and concerns about discussing sexual or hormonal health can create additional barriers to care. Hims aims to address some of these challenges by expanding access to hormone-related services and offering multiple treatment options based on individual medical needs.
The company’s latest expansion adds injectable testosterone formulations and an FDA-approved oral treatment to its existing testosterone-related services. The offerings build on the company’s previously introduced Testosterone Rx+ program, which uses enclomiphene to support the body’s natural testosterone production in appropriately selected patients.
Through this expanded portfolio, Hims intends to provide a broader range of options for men who are experiencing symptoms associated with low testosterone and are seeking medically supervised treatment.
Understanding the Broader Impact of Low Testosterone
Testosterone is essential to several physiological processes throughout adulthood. It contributes to the development and maintenance of muscle mass, supports bone density, influences sexual desire and helps regulate red blood cell production. Testosterone levels also interact with other aspects of metabolic and reproductive health.
When testosterone levels fall below the normal range and are accompanied by relevant symptoms, men may experience changes that affect their physical health, emotional well-being and quality of life.
According to the information shared by Hims, nearly 20 million men in the United States are affected by low testosterone. Symptoms can vary considerably between individuals, making clinical assessment important when determining whether hormone deficiency is responsible for a person’s concerns.
Some men may notice a reduction in energy or motivation, while others may experience changes in sexual function, difficulty maintaining muscle mass or an increase in body fat. Mood changes and reduced interest in activities can also occur, although these symptoms may have many other causes.
Low testosterone has also been associated with health conditions such as obesity, metabolic syndrome, diabetes and cardiovascular disease. However, an association does not necessarily establish that low testosterone directly causes these conditions. Underlying illnesses, medications, lifestyle factors and other hormonal changes can influence testosterone levels and overall health.
For this reason, diagnosing testosterone deficiency requires more than identifying a single symptom or relying on one laboratory result. Healthcare professionals generally consider symptoms, medical history, physical examination findings when appropriate, and properly interpreted testosterone measurements.
Hims says its expanded program is intended to help eligible men obtain an evaluation and explore appropriate treatment options within a structured care process.
Survey Highlights Men’s Interest in Energy and Hormone Health
Hims reports that a survey it commissioned involving 2,000 U.S. men aged 18 and older found growing interest in conversations about hormone health and how it changes with age.
The survey also identified energy as a leading priority for many respondents. According to the company’s findings, 79% of surveyed men said having more energy was a higher priority than gaining more muscle.
The result highlights a broader perspective on men’s health. While testosterone is frequently discussed in connection with bodybuilding and athletic performance, many men are more concerned about maintaining energy, participating in everyday activities and feeling well enough to engage with family, friends and professional responsibilities.
The same survey found that only 45% of respondents said they were familiar with specific treatments for low testosterone.
These findings suggest a potential gap between awareness of hormone health and understanding of the available medical options. However, the results reflect the views of the surveyed population and should not automatically be generalized to every man in the United States.
Hims believes that improving access to education, testing and provider consultations can help address this gap. Its expanded treatment program is intended to give eligible patients more choices while allowing healthcare professionals to evaluate whether hormone therapy is appropriate.
The company also emphasizes that treatment should focus on the patient’s broader health rather than simply increasing a testosterone measurement.
New Injectable Testosterone Replacement Therapy Options
A central component of the expansion is the introduction of injectable testosterone replacement therapy in two formulations: a compounded product and a commercially manufactured generic testosterone cypionate product.
The options differ in their formulation and administration schedules, giving eligible patients and their healthcare providers additional approaches to consider.
Compounded injectable testosterone
The compounded formulation is described by Hims as a subcutaneous injection administered twice weekly for eligible patients.
Subcutaneous injections deliver medication into the tissue beneath the skin. This differs from intramuscular administration, in which medication is injected into muscle tissue.
Hims states that its compounded formulation can increase testosterone levels within days. The actual response, however, may vary according to individual physiology, dosing, absorption and other clinical factors.
Compounded medications are prepared by compounding pharmacies to meet particular needs. They are not FDA-approved in the same way as commercially manufactured drug products, and their quality, safety and effectiveness are not established through the same product-specific FDA approval process. Patients should discuss the formulation’s risks, benefits and appropriate monitoring with their prescribing clinician.
Generic testosterone cypionate
The second injectable option is generic testosterone cypionate, a commercially manufactured testosterone medication administered intramuscularly.
According to Hims, this option is intended for once-weekly administration and can raise testosterone levels within 24 hours.
Testosterone cypionate is an established form of testosterone replacement used to treat certain cases of male hypogonadism, in which the body does not produce sufficient testosterone because of an underlying medical condition.
Its suitability depends on a clinical assessment that considers symptoms, laboratory findings, medical history and treatment goals. Patients also require appropriate follow-up to evaluate hormone levels, treatment response and potential adverse effects.
Although injectable treatment can be effective for appropriately selected patients, it is not suitable for everyone. Decisions about formulation, dosage and administration frequency must be made by a qualified healthcare professional.
Oral TRT Adds a Non-Injection Treatment Choice
In addition to injectable formulations, Hims is introducing access to Kyzatrex®, an FDA-approved oral testosterone replacement therapy.
The treatment provides an option for eligible men who require testosterone replacement but prefer not to administer injections.
Kyzatrex contains testosterone undecanoate and is an oral prescription medication indicated for specific forms of male hypogonadism associated with certain medical conditions. It is not intended for use simply to increase testosterone in otherwise healthy men or to treat age-related testosterone decline without an appropriate diagnosis.
Hims reports that Kyzatrex has been shown to help up to 96% of men reach normal testosterone levels within 90 days. That figure should be interpreted in the context of the particular clinical evidence, patient population and definition of normal testosterone used in the relevant study; it is not a guarantee that every patient will achieve the same result.
Oral testosterone has its own prescribing considerations, including administration instructions, potential interactions, blood pressure monitoring and assessment of treatment response. Patients should follow the approved prescribing information and their clinician’s instructions.
The availability of an oral option expands the range of treatment approaches that providers can consider when developing an individualized plan.
However, oral, injectable and other hormone-related therapies are not interchangeable in every clinical situation. The most appropriate treatment depends on the diagnosis, patient preferences, medical risks and the expected benefits of therapy.
Building on the Existing Testosterone Rx+ Program
The newly introduced therapies expand Hims’ existing Testosterone Rx+ program, which includes enclomiphene-based treatment.
Enclomiphene acts on hormonal signaling involved in the body’s regulation of testosterone production. Rather than supplying testosterone directly, it can stimulate the body’s natural hormone-production pathway in appropriately selected patients.
Hims has previously described enclomiphene as an option that can help increase testosterone levels by supporting endogenous production. The response depends on the patient’s underlying hormonal function and clinical circumstances.
This distinction is important because testosterone replacement and treatments that stimulate natural testosterone production have different mechanisms and implications.
Exogenous testosterone can suppress the body’s own production of testosterone and may reduce sperm production. For men who want to preserve fertility, this can be a particularly important consideration when selecting treatment. Enclomiphene and other approaches may be considered in certain circumstances, but they are not appropriate for every patient and require clinical supervision.
By offering several approaches, Hims says its partnered clinicians can consider a wider range of treatment options for men with low testosterone.
The expanded portfolio also reflects the company’s efforts to build its men’s health services beyond a single treatment model.
Hims reports that testosterone was scaling faster than any of its specialty areas outside weight loss as of the second quarter, three quarters after the launch of its testosterone offering. This suggests that hormone health has become an important area of growth for the company, although the announcement does not provide enough detail to quantify the program’s overall financial contribution.
At-Home Blood Collection and Comprehensive Laboratory Testing
An important part of the Hims care model is its at-home testing process, which is intended to reduce some of the logistical barriers associated with evaluating hormone health.
Traditionally, patients seeking testosterone testing may need to schedule an appointment, travel to a laboratory and discuss symptoms that they consider sensitive or difficult to raise in person. These requirements can discourage some people from seeking an assessment.
Hims aims to make the initial evaluation more convenient while maintaining clinical review and laboratory testing.
The process begins with a detailed medical intake that assesses symptoms, health history and potential risk factors. Patients then collect a blood sample at home using the Tasso device, an FDA-cleared capillary blood collection device worn on the upper arm.
The company says its laboratory evaluates 22 biomarkers from the sample. These include total testosterone, free testosterone, sex hormone-binding globulin (SHBG), an advanced lipid panel and markers related to blood sugar regulation.
Each measurement provides different information. Total testosterone measures the overall amount of testosterone in circulation, while free testosterone reflects the portion not bound to proteins. SHBG is a protein that binds testosterone and influences how much is available in an unbound form.
Lipid and glycemic markers provide additional context about cardiovascular and metabolic health. Taken together, these measurements can offer a broader view of a patient’s health than a testosterone measurement alone.
Nevertheless, a single at-home sample may not be sufficient to establish a diagnosis in every case. Testosterone levels can fluctuate, including according to the time of day, illness and other factors. Clinicians may require repeat testing, preferably under appropriate conditions, to confirm low testosterone.
The testing approach should therefore be understood as part of a broader clinical evaluation rather than a substitute for all conventional laboratory or in-person assessment.
Licensed Providers Guide Treatment Decisions
Following the collection and analysis of laboratory samples, Hims says a licensed healthcare provider reviews the patient’s symptoms, medical history and test results during a live consultation.
Treatment is prescribed only when the provider determines that it is medically appropriate.
This clinical review is an essential part of testosterone care because symptoms associated with low testosterone can overlap with other health conditions, including sleep disorders, depression, medication effects and metabolic problems.
A comprehensive assessment can help determine whether testosterone deficiency is likely to explain a patient’s symptoms and whether further testing or an alternative treatment approach is needed.
For patients who begin therapy, Hims describes an ongoing process involving follow-up assessments, additional laboratory testing and continued access to a support team. These services are intended to help patients and providers monitor progress and adjust treatment over time.
Monitoring is particularly important with testosterone therapy because treatment can produce adverse effects and requires ongoing evaluation. Depending on the patient and formulation, clinicians may assess testosterone levels, hematocrit, blood pressure, fertility considerations and prostate-related factors where appropriate.
Testosterone treatment is generally not recommended for men planning fertility in the near term without careful specialist evaluation, because externally administered testosterone can suppress sperm production. Patients with certain medical conditions may also require additional assessment before therapy is considered.
The company says its model is designed to combine convenience with provider oversight, giving patients access to testing and treatment options while maintaining a clinical decision-making process.
Safety and Individualized Care Remain Central
Although testosterone therapy can benefit men with confirmed testosterone deficiency, it is not a universal solution for fatigue, reduced muscle mass or changes associated with aging.
A diagnosis should be based on compatible symptoms and consistently low testosterone levels, interpreted by a qualified healthcare professional.
Treatment also requires a discussion of potential benefits, risks and alternatives. Testosterone therapy can cause increases in red blood cell levels, acne, fluid retention and suppression of natural testosterone production and sperm production. Certain patients may require closer monitoring because of existing health conditions or other risk factors.
The FDA has also emphasized that testosterone products should be used for approved indications and that their risks and benefits need to be considered carefully. Patients should not use prescription testosterone solely for bodybuilding, athletic performance or general anti-aging purposes.
For men concerned about hormone health, the first step is an appropriate medical assessment rather than selecting a treatment based only on symptoms or marketing claims.
Hims’ expanded treatment options may offer greater convenience for eligible patients, but treatment decisions should remain individualized and based on established clinical criteria.
Expanding Access to Personalized Men’s Healthcare
The introduction of injectable and oral testosterone replacement therapy represents a major expansion of Hims’ men’s health program.
By combining compounded and commercially manufactured injectable options with FDA-approved oral treatment, the company is increasing the range of therapies its partnered clinicians can consider for eligible men with low testosterone.
The expansion builds on its existing enclomiphene-based program and its digital care model, which includes at-home blood collection, laboratory testing, provider consultations and ongoing monitoring.
The company’s survey findings also point to a broader conversation about men’s health, with respondents prioritizing energy and daily well-being alongside physical performance. At the same time, limited familiarity with specific low testosterone treatments suggests that education and access to appropriate evaluation remain important.
Ultimately, testosterone care involves more than increasing a hormone level. Effective management requires identifying the cause of symptoms, confirming the diagnosis, selecting an appropriate treatment and monitoring the patient’s response.
As Hims expands its services, its approach aims to make hormone health evaluation and treatment more accessible while keeping medical assessment central to prescribing decisions. For men experiencing possible symptoms of testosterone deficiency, the availability of additional treatment choices may create new opportunities to discuss their concerns with a qualified healthcare professional and determine the most appropriate path forward.
Source link: https://news.hims.com/
